Another coronavirus vaccine was extremely effective

BRATISLAVA. Following the vaccine from Pfizer and BioNTech, the vaccine from the American company Moderna also showed extremely high efficacy against Covid-19.

Read about the BBC volume.

Moderna’s clinical trials showed 94.5 percent effectiveness, the company said, planning to apply for vaccine approval in the coming weeks.

Almost 95% efficiency

Related article The Pfizer vaccine was extremely effective, as demonstrated in the third phase of testing To read

30,000 volunteers in the United States participated in the Moderna vaccine trial. Half of the participants received two doses of the vaccine four weeks apart, the other half received a placebo, just an apparent drug. None of the participants knew which group they belonged to.

After the first 95 respondents were infected with the new coronavirus, Moderna decided to analyze the preliminary efficacy of its vaccine.

It was found that out of 95 infected volunteers, five had actually been vaccinated with the vaccine. The remaining 90 people who developed the infection were in the placebo group. Based on these findings, Moderna came to the encouraging conclusion that its vaccine is still 94.5% effective.

At the same time, eleven participants showed severe symptoms of the disease, but all belonged to the group that did not receive the actual vaccine.

So far, Moderna’s vaccine has not been shown to bring health complications with it.

Several vaccinated respondents showed short-term fatigue, headaches and muscle aches. However, these are common symptoms that can occur soon after vaccination.

Vaccine tests continue.

Immunity is questionable

It is not yet possible to say how long people’s immunity will last after being vaccinated with the Moderna vaccine. To do this, it is necessary to follow the research participants for a long time.

At the same time, it is not known how the vaccine works in the elderly, who belong to the most vulnerable group.

The data so far do not suggest that the vaccine should lose its efficacy with age, the head of the Moderna Tal Zaksa told the BBC.

The advantage of this vaccine is also the ease of storage.

Unlike the Pfizer-BioNTech vaccine, which requires above-standard equipment as it must be stored at a temperature of approximately minus 75 degrees Celsius, the Moderna vaccine only needs a temperature of minus 20 degrees. Therefore, commonly available freezers, which are found in most pharmacies or dispensaries, will be sufficient for its storage.

The Moderna vaccine will last in the refrigerator for about a month, while its more demanding competitor can only be stored at higher temperatures for five days.

Registration process

A week ago, the American company Pfizer and the German company BioNTech announced that their vaccine was 90% effective. The report then had a significant impact on equity markets. The vaccine is being tested on over 43,000 people.

Related article Eleven Most Promising Vaccines: Which Will Reverse a Pandemic? To read

The European Medicines Agency (EMA) announced on Monday that it has initiated a preliminary examination of Moderna’s application to register its product on the European Union market.

The so-called rolling review, announced by the EMA, accelerates the process of registering promising medicines and vaccines. EMA also examines Pfizer and Astra Zeneca vaccines.

It will only be possible to register substances when EMA has sufficient evidence of their efficacy, quality and safety.

The advantage is that the investigation can be started before the end of the third phase of the clinical trial and the pharmaceutical companies can provide the data gradually.

If you don’t see the chart correctly, click here.